DoD Lupus Research, Transformative Vision Award
ID: 354477Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354477
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Lupus Transformative Vision Award to support innovative research aimed at significantly improving the quality of life for individuals living with lupus. This grant program encourages applications that propose impactful interventions at both the individual and healthcare system levels, with a requirement for preliminary data and the inclusion of human subject research and clinical trials. With an estimated total program funding of $2 million and a maximum funding request of $2 million per award, the application process involves a two-step submission of a pre-application and a full application, with a close date set for August 6, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524LRPTVA_GG.pdf
    The Department of Defense (DOD) is offering the FY24 Lupus Transformative Vision Award under the Lupus Research Program to support innovative research that enhances the quality of life for lupus patients. The funding opportunity, totaling $10 million for fiscal year 2024, emphasizes high-impact scientific research aimed at understanding and treating lupus using healthcare delivery models and patient-focused interventions. Eligible applicants, including academic, nonprofit, and governmental organizations, must submit a two-step application process: a pre-application and a full application through the appropriate portals by specific deadlines. Key components of the application include a detailed project narrative, supporting documents, and a budget plan, with a maximum funding request of $2 million over four years. The review process assesses applications for potential impact, research strategy, and the qualifications of the research team, with a required consumer advocate to ensure patient perspectives are included. Final funding decisions will depend on both technical merit and program relevance. This award program reflects the DOD's commitment to advancing medical research for conditions affecting service members and the public.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Staff Research Program, aimed at fostering collaborative basic research between its scientific staff and institutions of higher education. The program seeks to enhance the professional competence of Army Research Office (ARO) scientists by engaging in hands-on research that advances knowledge in various scientific disciplines, including engineering, physical, life, and information sciences. This initiative is crucial for maintaining the integrity of ARO's mission while promoting innovative research aligned with Army interests. Interested applicants must submit proposals via Grants.gov by February 19, 2025, with no cost-sharing requirement, and can direct inquiries to William A. Creech at william.a.creech3.civ@mail.mil or by phone at 919-549-4387.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    Military and Civilian Partnership for Trauma Readiness Grant Program/Mission Zero
    Admin for Strategic Preparedness and Response
    The Administration for Strategic Preparedness and Response is offering the Military and Civilian Partnership for Trauma Readiness Grant Program, also known as the Mission Zero Act, to support high-acuity trauma centers in enhancing military-civilian partnerships for improved trauma care. This grant program aims to award up to 30 eligible trauma centers, enabling military trauma teams to provide full-time trauma and acute care services, thereby strengthening the nation's response to public health and medical emergencies. With an estimated total program funding of $4 million and an award ceiling of $4 million per grant, interested applicants, including nonprofits without 501(c)(3) status and hospitals, should note that the application period is expected to open on January 15, 2025, with a closing date of April 14, 2025. For further inquiries, applicants can contact Leslie Beck at 301-346-4857 or via email at leslie.beck@hhs.gov.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to support the late-stage translation of biomedical and behavioral research results related to arthritis, musculoskeletal, and skin diseases into marketable products. This Small Business Innovation Research (SBIR) grant (PAR-23-032) aims to foster collaboration between academic/non-profit labs and small business concerns (SBCs) to advance diagnostics, treatments, and prevention tools, while specifically excluding clinical trials. The initiative is crucial for bridging laboratory discoveries with real-world applications, ultimately enhancing public health outcomes through medical innovations. Interested applicants can seek funding up to $350,000, with ongoing application cycles from January 2024 to September 2025, and should direct inquiries to grantsinfo@nih.gov for further information.